Get started
Author

Pascal Rufi

Observed name: P. Rufi
Institution: Sanofi (France)
OpenAlex ID: A5055730299
Patient-reported outcomes in relapsing forms of MS: Real-world, global treatment experience with teriflunomide from the Teri-PRO study
2017 · Patricia K. Coyle, Bhupendra Khatri, et al. · Multiple Sclerosis and Related Disorders · 43
Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice
2018 · Patricia K. Coyle, Bhupendra Khatri, et al. · Multiple Sclerosis and Related Disorders · 35
PDF
Teriflunomide real-world evidence: Global differences in the phase 4 Teri-PRO study
2019 · Patricia K. Coyle, Bhupendra Khatri, et al. · Multiple Sclerosis and Related Disorders · 22
PDF
Predicting long-term disability outcomes in patients with MS treated with teriflunomide in TEMSO
2017 · Maria Pia Sormani, Philippe Truffinet, et al. · Neurology Neuroimmunology & Neuroinflammation · 22
PDF
Single-arm study to assess comprehensive infusion guidance for the prevention and management of the infusion associated reactions (IARs) in relapsing-remitting multiple sclerosis (RRMS) patients treated with alemtuzumab (EMERALD)
2019 · Sandra Vukusic, David Brassat, et al. · Multiple Sclerosis and Related Disorders · 15
PDF
Outcomes in Patients with Progressive MS: Analysis of Teriflunomide Long-Term Extension Data (P3.038)
2016 · Flavia Nelson, Christine Lebrun-Frenay, et al. · Neurology · 5
In vitro evaluation of the activity of teriflunomide against SARS-CoV-2 and the human coronaviruses 229E and OC43
2022 · Paul Lang, Svend S. Geertsen, et al. · Biochemistry and Biophysics Reports · 3
MSCopilot® digital biomarkers obtained in a real-world setting correlated with their clinical counterparts in the MS-DETECT study
2026 · Patrick Vermersch, Massimo Filippi, et al. · Multiple Sclerosis and Related Disorders
Real-world Digital Biomarkers Associated With Their Clinical Counterparts in the MS-DETECT Study (P4-18.004)
2026 · Patrick Vermersch, Massimo Filippi, et al. · Neurology
22611 - Biomarcadores Digitales Mscopilot® Obtenidos En Un Entorno Real Correlacionados Con Sus Homólogos Clínicos En El Estudio Ms-detect
2025 · C. Oreja Guevara, P. Vermersch, et al. · Neurology Perspectives
Clinical outcomes and treatment satisfaction in patients switching to teriflunomide in the real-world Teri-PRO and TAURUS-MS I studies (160)
2020 · Mark S. Freedman, Boris A. Kallmann, et al. · Neurology
PO246 Measuring treatment satisfaction in rms: teri-pro results
2017 · Jeremy Hobart, Karthinathan Thangavelu, et al. · Journal of Neurology Neurosurgery & Psychiatry
PO153 Teri-pro patients switching to teriflunomide from prior dmt
2017 · Patricia K Coyle, Bhupendra Khatri, et al. · Journal of Neurology Neurosurgery & Psychiatry
Clinical and Safety Outcomes From Patients Treated With Teriflunomide in the Phase 4 Teri-PRO Study (P5.384)
2017 · Ralf Gold, Bhupendra Khatri, et al. · Neurology
Long-term Outcomes in Patients with Progressive MS with Relapses: Analysis of TEMSO and TOWER Extension Data (S33.008)
2017 · Flavia Nelson, Christine Lebrun-Frenay, et al. · Neurology
Patient-Reported Outcomes (PROs) in Patients Switching to Teriflunomide From a Prior Disease-Modifying Therapy (DMT): Results From the Phase 4 Teri-PRO Study (P3.363)
2017 · Patricia K Coyle, Bhupendra Khatri, et al. · Neurology
Patient-Reported Outcomes With Teriflunomide in Patients With No Prior Disease-Modifying Therapy Use Within 2 Years: Results From the Phase 4 Teri-PRO Study (P3.348)
2017 · Ralf Gold, Bhupendra Khatri, et al. · Neurology
Predicting Treatment Response to Teriflunomide in the TEMSO Study Using the Modified Rio Score (P2.108)
2016 · Maria Pia Sormani, Philippe Truffinet, et al. · Neurology
Early vs Delayed Treatment with Teriflunomide 14 mg Results in Reduced Risk of Disability Progression in Patients with MS (P3.021)
2016 · Paul O'Connor, Karthinathan Thangavelu, et al. · Neurology
Works count: 19
Citation count: 145
H-index: 5
I10-index: 5
Year
Topic
Type